Eikon Therapeutics, Inc.
A biotech company that watches individual protein molecules move inside living cells to hunt for cancer drugs, running clinical trials for an immunotherapy against melanoma and lung cancer as well as PARP inhibitors for other tumor types. Founded in 2019 by scientists including a Nobel Prize winner, it took its name from the Greek word for "image," a nod to the microscopy that lets it watch proteins in action.
Estimated from filings — the split-adjusted price range over the quarters each manager built the position. A range, not a fill price; 13F reports a quarter-end snapshot, not a trade date.